Amol Akhade/hiranandanihospital.org
May 19, 2025, 11:41
Amol Akhade: Top 10 Breast Cancer Trials to Watch at ASCO25
Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, posted on X:
“Top 10 Breast Cancer Trials to Watch at ASCO25.
Save the date. Big data in HER2+, TNBC and HR+ mBC!
- DESTINY-Breast09 – T-DXd+P vs THP (1L HER2+ MBC) [LBA]
- ASCENT-04 – SG+pembro vs chemo+pembro (1L TNBC) [LBA]
- SERENA-6 – Camizestrant+CDK4/6i in ESR1mut HR+ ABC [LBA]
- neoCARHP – De-escalation chemo in HER2+ eBC [LBA]
- SOFT+TEXT (15y) – Long-term OFS benefit
- DHP107 Trial – Oral vs IV paclitaxel
- VERITAC-2 – Vepdegestrant (PROTAC) vs fulvestrant [LBA]
- MA.40 / FINER – Fulvestrant + ipatasertib post-CDK4/6i [LBA]
- NRG-BR003 – Carbo in node+ or high-risk TNBC [LBA]
- NeoSTAR – Neoadjuvant SG+pembro in early TNBC.”
Learn more about Amol Akhade on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 19, 2025, 11:41
May 19, 2025, 11:34
May 19, 2025, 11:20
May 19, 2025, 11:16
May 19, 2025, 11:14
May 19, 2025, 10:58